ACRX Talphera Inc.


$ 1.35 $ 0.10 (8.06 %)    

Friday, 31-Oct-2025 17:50:28 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 1.34
$ 1.23
$ 1.25 x 22
$ 1.34 x 100
$ 1.22 - $ 1.34
$ 0.38 - $ 1.45
193,906
na
na
$ 0.40
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 acelrx-pharmaceuticals-announces-rebranding-with-name-change-to-talphera-to-trade-on-nasdaq-under-ticker-symbol-tlph-effective-jan-10-2024

Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel ...

 acelrx-pharmaceuticals-announces-publication-of-study-evaluating-anticoagulation-practices-for-continuous-renal-replacement-therapy-in-the-us

Use of CRRT increased during COVID and remained at these higher utilization levelsStudy results demonstrate challenges physicia...

 why-green-giant-shares-are-trading-lower-by-around-37-here-are-20-stocks-moving-premarket

Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Gre...

 hc-wainwright--co-reiterates-buy-on-acelrx-pharmaceuticals-maintains-5-price-target

HC Wainwright & Co. analyst Ed Arce reiterates AcelRx Pharmaceuticals (NASDAQ:ACRX) with a Buy and maintains $5 price ta...

 acelrx-pharmaceuticals-q3-2023-gaap-eps-008-beats-028-estimate-sales-11700k-miss-13000k-estimate

AcelRx Pharmaceuticals (NASDAQ:ACRX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate o...

 earnings-scheduled-for-november-8-2023

Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.

 on-oct-18-acelrx-pharmaceuticals-received-written-notice-from-nasdaq-notifying-co-that-it-is-not-in-compliance-with-minimum-bid-price-requirement-will-evaluate-available-options-to-regain-compliance-with-minimum-bid-price-requirement

- SEC Filing

 alliance-global-partners-initiates-coverage-on-acelrx-pharmaceuticals-with-buy-rating-announces-price-target-of-425

Alliance Global Partners analyst James Molloy initiates coverage on AcelRx Pharmaceuticals (NASDAQ:ACRX) with a Buy rating a...

 why-galecto-shares-are-trading-higher-by-around-30-here-are-20-stocks-moving-premarket

Gainers

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION